• Muhammad Noor Diansyah, Ami Ashariati Prayogo, Made Putra Sedana, Merlyna Savitri, Pradana Zaky Romadhon, Putu Niken Ayu Amrita, Andi Yasmin Wijaya, Winona May Hendrata, and Ugroseno Yudho Bintoro.
• Department of Internal Medicine, Dr. Soetomo Teaching Hospital, Surabaya, Indonesia
• Turk J Med Sci. 2021 Apr 30; 51 (2): 562-569.

AimTo explore the potential of the circulating plasma miRNA-21 as an early detection biomarker by comparing early-stage breast cancer (BG) and healthy control (HG) in Indonesian population.Materials And MethodsThe enlisted patients were 26 adult female early-stage breast cancer patients (stage 1A, 1B, 2A, and 2B) of Airlangga University Hospital from August 2019 to October 2019. Sixteen volunteers were recruited as matching healthy subjects. MiRNA-21 expression was quantified by plasma qRT-PCR. Data analysis performed using IBM SPSS Statistics v.24 (IBM Corp., Armonk, NY, USA). MiRNA-21 cut-off, sensitivity, and specificity were analyzed using receiver operating characteristic (ROC) curve.ResultsThe study included 26 BG and 16 HG subjects. The miRNA-21 expression in BG group was 3.933 (1.181-11.794) and 0.905 (0.164-4.532) in HG group (4.34 folds; P = 0.001), with 1.66 cut-off (92.3% sensitivity; 81.2% specificity). MiRNA-21 expression separated analysis in HG showed a 0.578 times lower expression in menopause subjects [0.651 (0.164-0.414)], compared to premenopause ones [(1.123 (0.758 - 4.532); P = 0.031]. Yet, in BG group, 1.729 times higher miRNA-21 expression was observed in menopause subjects (6.021 ± 3.583), compared to premenopause ones (3.500 ± 1.517; P = 0.022).ConclusionsCirculating miRNA-21 expression is a potential biomarker for early detection of breast cancer and might act as a breast cancer risk predictor.This work is licensed under a Creative Commons Attribution 4.0 International License.

22 keywords...

hide…